Adipose stem cell therapy - Anterogen

Drug Profile

Adipose stem cell therapy - Anterogen

Alternative Names: Allogeneic mesenchymal stem cells - Anterogen; Adipocell (Anterogen); AdipoPlus; Adipose-derived stem cells; ALLO-ASC; ALLO-ASC-DFU; ALLO-ASC-EB; ALLO-ASC-OA; ALLO-ASC-TI; Allogeneic adipose stem cells; ANTG-ASC; Autologous adipose stem cells; Cupistem; Queencell

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Anterogen
  • Class Stem cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Rectal fistula
  • New Molecular Entity No

Highest Development Phases

  • Marketed Rectal fistula; Scars; Subcutaneous fat disorders
  • Phase II Diabetic foot ulcer
  • Phase I/II Tendon injuries
  • Phase I Burns; Crohn's disease; Epidermolysis bullosa
  • Preclinical Chronic wounds; IgA nephropathy; Osteoarthritis

Most Recent Events

  • 13 Dec 2017 Anterogen plans a phase III trial for Diabetic Foot Ulcer in Decemeber 2017 (NCT03370874)
  • 21 Nov 2016 Anterogen terminates a phase-II clinical trial in Rectal fistula in South Korea prior to November 2016 (NCT01314092) (Injection)
  • 07 Dec 2015 Anterogen plans a phase II trial for Burns in South Korea (NCT02619851)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top